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OBJECTIVES This study was designed to assess the effect of metformin on impaired endothelial function
in type 2 diabetes mellitus.
BACKGROUND Abnormalities in vascular endothelial function are well recognized among patients with type
2 (insulin-resistant) diabetes mellitus. Insulin resistance itself may be central to the
pathogenesis of endothelial dysfunction. The effects of metformin, an antidiabetic agent that
improves insulin sensitivity, on endothelial function have not been reported.
METHODS Subjects with diet-treated type 2 diabetes but without the confounding collection of
cardiovascular risk factors seen in the metabolic syndrome were treated with metformin
500 mg twice daily (n 5 29) or placebo (n 5 15) for 12 weeks. Before and after treatment,
blood flow responses to intraarterial administration of endothelium-dependent (acetylcho-
line), endothelium-independent (sodium nitroprusside) and nitrate-independent (verapamil)
vasodilators were measured using forearm plethysmography. Whole-body insulin resistance
was assessed on both occasions using the homeostasis model (HOMA-IR).
RESULTS Subjects who received metformin demonstrated statistically significant improvement in
acetylcholine-stimulated flows compared with those treated with placebo (p 5 0.0027 by
2-way analysis of variance), whereas no significant effect was seen on nitroprusside-stimulated
(p 5 0.27) or verapamil-stimulated (p 5 0.40) flows. There was a significant improvement
in insulin resistance with metformin (32.5% reduction in HOMA-IR, p 5 0.01), and by
stepwise multivariate analysis insulin resistance was the sole predictor of endothelium-
dependent blood flow following treatment (r 5 20.659, p 5 0.0012).
CONCLUSIONS Metformin treatment improved both insulin resistance and endothelial function, with a
strong statistical link between these variables. This supports the concept of the central role of
insulin resistance in the pathogenesis of endothelial dysfunction in type 2 diabetes mellitus.
This has important implications for the investigation and treatment of vascular disease in
patients with type 2 diabetes mellitus. (J Am Coll Cardiol 2001;37:1344–50) © 2001 by the
American College of Cardiology
Vascular disease is a major cause of morbidity and mortality
among patients with diabetes mellitus (DM), and these
patients account for a significant proportion of all patients
with cardiovascular disease (1). Abnormalities in
endothelium-dependent vascular responses, perhaps the
earliest demonstrable alteration in vascular health, have
been found among patients with type 2 DM (2,3). The
origins of these alterations remain poorly understood. The
contributions of a number of potentially important variables
have been examined, including hyperglycemia (4), altered
antioxidant balance (5,6), and alterations in circulating lipid
composition including elevated free fatty acids (FFA) (7).
More recently, the question of the contribution of insulin
resistance (IR) to vascular abnormalities in DM has been
raised. Insulin resistance is felt to be central to the patho-
genesis of the metabolic syndrome (Syndrome X), a clus-
tering of traditional cardiovascular risk factors in patients
with type 2 DM (8). Furthermore, IR per se has a direct
impact on endothelial function, distinct from effects related
to unfavorable changes in lipid composition or blood pres-
sure (9). Therefore, IR presents an important variable both
with regard to understanding the pathogenesis of cardiovas-
cular disease and as a potential therapeutic target.
The question arises as to the effect of therapies targeting
IR on endothelial function in particular and cardiovascular
disease in general. Metformin, a medication of the bigua-
nide family, is now widely available. Its mechanism of action
is poorly understood, but includes a reduction in whole-
body IR (10). The effects of altering IR with metformin on
endothelial function in humans have not been previously
reported. In a placebo-controlled study, we measured fore-
arm resistance vessel endothelial function in patients with
type 2 (insulin-resistant) DM, but without other classical
cardiovascular risk factors, before and after three months’
treatment with metformin.
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METHODS
Patients. Patients with stable weight and diet-controlled
type 2 DM (according to American Diabetes Association
criteria, namely a fasting serum glucose .7.0 mmol/L on
two occasions, a casual glucose .11.1 mmol/l with symp-
toms, or a 2-h post-oral glucose tolerance test (75 g glucose
load) glucose of .11.1 mmol/l) were recruited from our
regional outpatient diabetes day care center. Weight and
fasting glucose levels were stable over a minimum of four
weeks prior to recruitment. To minimize the confounding
effects of other known cardiovascular risk factors on mea-
sures of endothelial function, and in particular the potential
for changes related to metformin treatment, we studied
patients with DM but without the clustering of risk factors
seen in the metabolic syndrome. Both men and women were
recruited, as diabetes is known to abrogate the relatively
preserved vascular responses otherwise evident among
women (11). Exclusion criteria included known coronary or
peripheral vascular disease, hypertension (blood pressure
.130/85), current treatment with vasoactive medications,
hypercholesterolemia (total cholesterol .6.2 mmol/l), hy-
pertriglyceridemia (triglycerides .2.3 mmol/l), a history of
smoking within three months of enrollment, micro- or
macroalbuminuria, known diabetic retinopathy, age at di-
agnosis of diabetes #25 years, current participation in
another clinical trial and contraindications to metformin
therapy, including renal or hepatic impairment and known
intolerance to metformin.
This trial was designed and performed in accordance with
the principles of the Declaration of Helsinki and was
approved by our University’s Ethical Review Board. Written
informed consent was obtained after the purpose, nature
and potential risks of the interventions were explained to the
subjects.
Protocol. Forty-four subjects underwent vascular response
measurements using forearm plethysmography (described in
the following text) before and after three months’ treatment
with metformin 500 mg orally twice daily or placebo.
Patients were assigned in a 2:1 ratio to metformin or
matching placebo. End point measures including blood flow
data analyses were blinded to patient name, treatment
assignment and treatment timing.
On the pretreatment study day, blood work confirming
normal hepatic and renal function as well as a spot urine
determination of the albumin:creatinine ratio was obtained.
If a cholesterol profile was not available from #3 months
before the study date, this was measured concurrent with
determinations of fasting serum glucose and insulin levels,
hemoglobin A1c, free fatty acids and total homocysteine.
Cuff blood pressure, hip and waist circumferences, height
and weight were determined before the vascular study.
These parameters were measured again following three
months’ therapy with metformin or placebo. Compliance
with study medication was assessed with pill counts at the
end of the treatment period.
Vascular responses. All studies were performed in a quiet
clinical laboratory maintained at 21 to 23°C. Subjects were
asked to refrain from drinking alcohol- or caffeine-
containing beverages for at least 12 h before the study.
Aspirin and any prescribed or over-the-counter nonsteroidal
anti-inflammatory medications were stopped at least five
days before each plethysmography session. Studies were
performed following an overnight (10 to 12 h) fast. For the
posttreatment study day, the last study medication tablet
was taken with the evening meal on the day before the
study.
Forearm blood flow (FBF) responses were determined
using standard techniques of forearm strain-gauge plethys-
mography. Mercury-in-silastic strain gauges (Hokanson,
Inc., Seattle, Washington) were connected to plethysmo-
graphs (Model EC-4, Hokanson, Inc.) calibrated to mea-
sure percent change in volume, expressed as flow in ml per
100 ml tissue per minute. Both arms were supported at heart
level. Starting 10 s before each set of measurements,
circulation to the hand was prevented by inflation of a wrist
cuff to 160 mm Hg. For each measurement, a cuff placed on
the upper arm was inflated to 40 mm Hg to occlude venous
egress. This was achieved by rapidly inflating a cuff (Inflator
model E10, Hokanson, Inc.) for 10 of every 20 s.
On each study day a standard dose-response profile was
obtained for brachial arterial infusions of the endothelium-
dependent vasodilator acetylcholine (Ach) (3, 10 and 30
mg/min) (Iolab, Claremont, California), the endothelium-
independent vasodilator sodium nitroprusside (SNP) (1, 3
and 10 mg/min) (Roche, Basel, Switzerland) and the
nitrate-independent vasodilator verapamil (VER) (1, 10 and
100 mg/min) (Abbott Laboratories, Montreal, Canada). All
solutions were infused at 1.0 ml/min (Harvard Apparatus,
South Natick, Massachusetts) into the brachial artery of the
nondominant arm via an epidural catheter (Concord Portex,
Keene, New Hampshire) sealed with dental wax to a
27-guage dental needle (Sherwood Medical, St. Louis,
Missouri).
A baseline measurement of flow was obtained at least
10 min after placement of the intraarterial needle. The
sequence of Ach and SNP was randomized on the pretreat-
Abbreviations and Acronyms
Ach 5 acetylcholine
ANCOVA 5 analysis of covariance
ANOVA 5 analysis of variance
BMI 5 body mass index
CV 5 coefficient of variation
DM 5 diabetes mellitus
FBF 5 forearm blood flow
FFA 5 free fatty acid
HOMA-IR 5 homeostasis model assessment of insulin
resistance
IR 5 insulin resistance
LDL 5 low density lipoprotein
SNP 5 sodium nitroprusside
VER 5 verapamil
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ment day for each patient and repeated on the second study
day. Because of its long-lasting vasodilating effect, VER was
infused last on both days. Each dose was infused for 6 min.
Vasodilator infusions were separated from each other by
infusions of normal saline for at least 18 min to allow flow
to return to baseline, with flow measurements performed
during the last 3 min of each infusion. Measurements were
performed simultaneously in both the infused and contralat-
eral arms. Flow data analysis was performed at a later date
by investigators blind to patient name, study day and
treatment assignment. Forearm blood flow was taken as the
mean of the last five flow measurements at a given drug
dose. Data were expressed as the percent increase in flow
relative to the immediately preceding baseline measure-
ment.
Laboratory. Fasting blood work was collected following
the flow measurements. All assays were performed in our
local hospital’s clinical laboratory. Standard methodologies
for glucose, hemoglobin A1c, cholesterol and triglyceride
measurements were used. Hemoglobin A1c measurements
have an upper limit of normal of 6.2% in our laboratory.
Insulin levels were measured using a double-antibody ra-
dioimmune assay (Pharmacia & Upjohn Inc., Mississauga,
Ontario, Canada), with an observed intra-assay coefficient
of variation (CV) 2.4% at 51 pmol/l and 6.1% at 741 pmol/l.
Interassay CV is reported at 5.8% across the range of
standards. Insulin measurements were performed in dupli-
cate. Whole-body IR was assessed using the homeostasis
model approximation (homeostasis model IR [HOMA-
IR]) (12). This tool has excellent correlations with more
formal and cumbersome techniques for the measurement of
IR (12,13), particularly when logarithmically transformed
(14–16). Free fatty acid levels were determined using
spectrophotometric quantitation (Wako Diagnostics, Rich-
mond, Virginia) following oxidation/peroxidation (17); nor-
mal range 0.10 to 0.70 mmol/l. Homocysteine levels were
determined by HPLC (Hewlett-Packard, Palo Alto, Cali-
fornia) (18); normal range 7.1 to 15.1 mmol/l.
Statistics. Data were expressed as mean (SEM). Statistical
analyses were performed using StatView 5.0 (SAS Corpo-
ration, Carey, North Carolina), with statistical significance
set at a two-sided p value of 0.05. Comparisons between
groups prior to treatment were performed using unpaired t
tests. The end point for statistical analyses was the percent
increase in flow observed across the dose-response range of
each vasodilator. Two-way repeated-measures analysis of
variance (ANOVA) was used to compare the response to
treatment between the two study groups, with analysis of
covariance (ANCOVA) used to assess the interaction effects
of multiple variables. Linear regression analysis was used to
assess the dependence of vascular responses on various
metabolic variables, followed by forward stepwise regression
analysis incorporating these variables.
Forearm blood flow measurements have a coefficient of
variation of ;22% (standard deviation ;2.4 at flow re-
sponses 12 to 15 ml/100 ml/min) in our laboratory. We
anticipated a $2.5 ml/100 ml/min improvement in flow
response. From these values, we calculated a sample size of
;20 per paired treatment group in order to demonstrate
this difference with a 5 0.05 and b 5 0.80. The 29:15
patient assignment of the overall study was chosen with the
aim of minimizing the error of the treatment effect estimate
while maintaining statistical power.
RESULTS
Demographics. Pretreatment subject characteristics are
detailed in Table 1. None of the subjects had previously
received metformin therapy. Subjects assigned to metformin
and placebo were well matched for degree of obesity and
level of glycemic control, and both the fasting insulin level
and the calculated index of IR indicated equivalent degrees
of IR. The level of low density lipoprotein (LDL) choles-
terol was significantly lower in the group who received
placebo. A borderline difference (p 5 0.065) in FFA levels,
also favoring the placebo group, was also present. No
baseline differences in metabolic or vascular parameters
attributable to gender were evident (data not shown).
Medication compliance was .95% by pill count. Four
subjects withdrew from the study before the second set of
measurements, two of whom had been assigned to receive
metformin therapy. One from each group withdrew because
of concerns over medication side effects, specifically gastro-
intestinal side effects. Four other subjects noted mild gas-
trointestinal discomfort (three on metformin, one on pla-
cebo) intermittently throughout the treatment period.
Metabolic parameters. Table 2 reports the outcome of a
subset of metabolic parameters following treatment. Met-
formin produced a significant 32.5% drop in HOMA-IR,
whereas no change was seen in the patients receiving
placebo. Treatment effects on glucose (0.5 mmol/l reduc-
tion) and weight (1.5 kg) were small and did not achieve
statistical significance. The pretreatment differences in LDL
Table 1. Pretreatment Patient Characteristics
Parameter
Placebo
(n 5 15)
Metformin
(n 5 28)
Age (yrs) 54.8 (2.6) 50.7 (1.8)
Gender (M/F) 11/4 15/14
SBP (mm Hg) 124 (4) 126 (2)
DBP (mm Hg) 78 (1) 80 (1)
BMI (kg/m2) 33.1 (1.9) 32.1 (1.3)
Hb Alc (%) 7.2 (0.5) 6.8 (0.2)
Glucose (mmol/l) 7.43 (0.55) 7.00 (0.23)
Insulin (pmol/l) 86.9 (9.2) 107.8 (13.2)
HOMA-IR 4.1 (0.6) 4.8 (0.6)
Cholesterol (mmol/l) 4.59 (0.22) 5.38 (0.18)
LDL-C (mmol/l) 2.68 (0.20) 3.36 (0.15)*
HDL-C (mmol/l) 1.18 (0.08) 1.15 (0.06)
FFA (pmol/l) 0.51 (0.06) 0.74 (0.05)
Homocysteine (pmol/l) 9.27 (0.62) 9.45 (0.70)
*p 5 0.049.
BMI 5 body mass index; DBP 5 diastolic blood pressure; FFA 5 free fatty acids;
Hb A1c 5 hemoglobin A1c; HDL-C 5 high density lipoprotein cholesterol;
HOMA-IR 5 homeostasis model assessment insulin resistance; LDL-C 5 low
density lipoprotein cholesterol; SBP 5 systolic blood pressure.
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cholesterol persisted following treatment, but without any
change attributable to metformin treatment. The significant
reduction in FFA is an increasingly recognized effect of this
medication.
Blood flow responses. For all results presented, parallel
analyses using the measures in the infused arm and the ratio
of infused to noninfused arm were carried out, and because
the two approaches provided equivalent results, only those
of the infused arm are presented. Baseline FBF in the
infused arm did not differ within or between study days (p 5
0.43), with values in both groups of 2.8 6 0.3 ml/100ml/
min. Forearm blood flow in the contralateral arm showed
the variation inherent to this technique, but did not change
within or between study days (p 5 0.83). Figures 1 to 3
present data for the infused arm as percent increase in FBF
from the immediately preceding baseline measurement.
The metformin-treated subjects experienced a statistically
significant improvement in endothelium-dependent vasodi-
lator response compared with the placebo-treated group
(Fig. 1, p 5 0.0027 by two-way ANOVA), owing princi-
pally to improved FBF responses in the metformin-treated
subjects compared to baseline (Fig. 1). The slightly dimin-
ished endothelium-dependent responses in the placebo
group at the end of the study (Fig. 1) were not statistically
different from this group’s baseline responses.
Baseline endothelium-independent nitrate responses
were unexpectedly higher in the group who received pla-
cebo, but at the end of treatment this difference was
abolished (Fig. 2). Although the change in response at peak
dose was statistically significant for metformin-treated sub-
jects compared with their baseline (p 5 0.01), across all
doses there was no statistically significant treatment effect
relative to placebo (p 5 0.27). Verapamil-induced, nitrate-
independent flows were not different between groups either
before or after treatment (p 5 0.40, Fig. 3).
Predictors of endothelial function. At baseline, univariate
ANOVA revealed no effect of any metabolic or anthropo-
morphic parameters on endothelial responses, and similarly
by ANCOVA there were no significant interactions of these
effects on baseline responses. After therapy with metformin,
univariate ANOVA revealed an effect of logHOMA-IR
(p 5 0.06) and of body mass index (BMI) (p 5 0.007) on
endothelial responses. Again, ANCOVA revealed no inter-
actions, suggesting that the chance imbalances between
groups, particularly with regard to LDL cholesterol, did not
influence the results. Among the subjects who received
Figure 2. Endothelium-independent blood flow responses before and after
treatment with metformin. Doses are 1, 3 and 10 mg/min. p 5 0.27 by
two-way analysis of variance, comparing treatment effects in the two
groups. SNP 5 sodium nitroprusside; FBF 5 forearm blood flow.
Table 2. Metabolic and Anthropomorphic Changes Following Treatment
Parameter
Placebo Metformin
p ValueBaseline Treated Baseline Treated
HOMA-IR 4.07 (0.63) 4.08 (0.67) 4.77 (0.66) 3.22 (0.38) 0.01
Glucose (mmol/l) 7.43 (0.55) 7.39 (0.68) 7.00 (0.23) 6.50 (0.20) 0.11
Hb A1c (%) 7.2 (0.5) 6.9 (0.3) 6.8 (0.2) 6.5 (0.2) 0.83
Insulin (pmol/l) 86.9 (9.2) 87.6 (9.9) 107.8 (13.2) 77.7 (7.2) 0.60
BMI (kg/m2) 33.0 (2.2) 33.0 (2.3) 32.8 (1.3) 32.1 (1.3) 0.13
Cholesterol (mmol/l) 4.59 (0.22) 4.64 (0.24) 5.38 (0.18) 5.41 (0.16) 0.85
LDL-C (mmol/l) 2.68 (0.20) 2.80 (0.23) 3.36 (0.15) 3.37 (0.11) 0.11
HDL-C (mmol/l) 1.18 (0.08) 1.19 (0.09) 1.15 (0.06) 1.20 (0.07) 0.39
FFA (pmol/l) 0.51 (0.06) 0.56 (0.08) 0.74 (0.05) 0.63 (0.05) 0.019
BMI 5 body mass index; FFA 5 free fatty acids; Hb A1c 5 hemoglobin A1c; HDL-C 5 high density lipoprotein cholesterol;
HOMA-IR 5 homeostasis model assessment insulin resistance; LDL-C 5 low density lipoprotein cholesterol. P values are
reported for comparison by two-way analysis of variance, comparing differences attributable to treatment.
Figure 1. Endothelium-dependent blood flow responses before and after
treatment with metformin. Doses are 3, 10 and 30 mg/min. *p 5 0.0027 by
two-way analysis of variance, comparing treatment effects in the two
groups. ACh 5 acetylcholine; FBF 5 forearm blood flow.
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metformin, a relationship of changes in metabolic parame-
ters to changes in endothelium-dependent responses was
suggested by trends with DlogHOMA-IR (p 5 0.12) and
DFFA (p 5 0.08). The inclusion of these variables with the
change in BMI and in lipid variables in a multivariate model
accounted for .95% of the variation in the change in
endothelial response (p 5 0.005).
Following therapy, linear regression analyses revealed
dependencies of endothelium-dependent responses follow-
ing therapy on BMI (r 5 20.43, p 5 0.007),
logHOMA-IR (r 5 20.486, p 5 0.017) (Fig. 4) and high
density lipoprotein cholesterol (r 5 0.34, p 5 0.036). Of
note, no relationship with LDL cholesterol, ambient glu-
cose, Hb A1c or FFA level was evident. Stepwise multiple
regression analysis produced a persistent relationship only
with IR (logHOMA-IR), regardless of its entry position in
the model. The final model gave an r value of 20.659 and
an adjusted r2 of 0.434 (p 5 0.0012). In other words,
following treatment the degree of IR was the single best
predictor of endothelial response.
DISCUSSION
In patients with IR and type 2 DM, three months of
treatment with metformin improved endothelium-
dependent vascular responses, whereas vascular responses of
patients treated with placebo remained unchanged. Met-
formin improved insulin sensitivity, as measured by
HOMA-IR, and by stepwise multivariate analysis the de-
gree of IR following treatment was the sole predictor of
endothelium-dependent responses.
Patients with cardiovascular risks other than type 2 DM
were specifically excluded in an attempt to separate the
effects of alterations in IR per se on the endothelium from
the effects secondary to changes in the clustered metabolic
parameters. Metformin treatment resulted in statistically
significant improvements only in HOMA-IR and FFA
levels compared to placebo, without significant changes in
body mass index, blood pressure or cholesterol levels. Of
note, no relationship of endothelial responses with either
acute or chronic glycemic control was seen, nor was there an
evident interaction with FFA levels or LDL cholesterol.
Unexpectedly, pretreatment responses to sodium nitro-
prusside differed between groups, and this difference was no
longer present at the end of treatment. This may simply
represent regression to the mean from an anomalous initial
reading. The alternative explanation, that treatment resulted
in improved nitrate responses, remains possible but cannot
be stated from our data.
Metformin and vascular responses. Favorable changes in
the overall cardiovascular risk factor profile with metformin
are well recognized (19,20). Few studies of metformin’s
effect on vascular responses in humans have been published.
Favorable effects have been reported on hemodynamic and
rheologic responses to L-arginine infusion in patients with
fasting hyperglycemia (21), basal and postoral glucose tol-
erance test forearm blood flow in obese patients with type 2
DM (22) and reduced blood pressure response to vasocon-
strictor stimuli in patients with DM (23). A beneficial effect
to improve postischemic blood flow responses has been
reported in patients with symptomatic peripheral vascular
disease (24). Our data confirm and extend these previously
observed effects of metformin on blood flow in a population
of insulin-resistant diabetic subjects.
Insulin resistance and endothelial function. The ques-
tion of a relationship between IR and endothelial function
has been of considerable interest in recent years. In cross-
sectional studies, strong correlations have been found in
patients with type 2 DM (25), obesity/IR (9), and essential
hypertension (26) as well as in healthy subjects (27). Other
researchers have not found a relationship in similar patient
groups (28–30). The existence of this relationship remains
controversial.
An alternative approach to this question comes from
Figure 3. Nitrate-independent blood flow responses before and after
treatment with metformin. Doses are 1, 10 and 100 mg/min. p 5 0.40 by
two-way analysis of variance, comparing treatment effects in the two
groups. VER 5 verapamil; FBF 5 forearm blood flow.
Figure 4. Regression analysis showing a dependence of endothelium-
dependent flows on insulin resistance following treatment. ACh 5 acetyl-
choline; FBF 5 forearm blood flow; logHOMA-IR 5 logarithmic
transformation of the homeostasis model assessment insulin resistance
index.
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studies of the effect of altering IR on blood flow responses.
The experimental induction of IR in rats (31) and in
humans (7) resulted in reductions in blood flow responses.
In the present study, we found that treatment with met-
formin simultaneously improved IR and endothelial func-
tion, and further were also able to demonstrate a significant
dependence of endothelium-dependent responses on IR
following therapy. This is in contrast, however, to one prior
publication (32) in which troglitazone, a perioxisome
proliferator-activated receptor (PPAR)-gamma nuclear re-
ceptor activator with insulin-sensitizing actions, was given
to obese insulin-resistant subjects in a randomized crossover
design. Before treatment, there was no evident defect in
cholinergic blood flow responses, but there was blunting of
insulin-mediated vasodilation. Despite a clear improvement
in insulin sensitivity with treatment, no improvement in
insulin-mediated or agonist-stimulated vasodilation was
seen. This lack of improvement in insulin-stimulated flow
despite a demonstrated improvement in insulin-stimulated
glucose uptake might suggest that these phenomena are
dissociated. This discrepancy cannot be attributed to the
agents used because a clear improvement has been seen with
troglitazone treatment in a group of insulin-resistant
women with polycystic ovarian syndrome (33).
In the present study, the direct correlation between the
change in IR and the improvement in endothelial response
did not achieve statistical significance, but the combination
of changes in IR, lipids, FFAs and BMI was able to account
for the vast majority of the change in endothelial response.
This is perhaps not surprising, in light of the known
metabolic interrelationships of these variables and their
independent effects on vascular function. However, an
important effect of IR per se on endothelial function is
suggested by the fact that a relationship was not evident at
baseline but was brought out by metformin therapy, which
concurrently improved insulin sensitivity and endothelial
function. Furthermore, the relationship persisted through
stepwise regression analysis including the relevant known
variables.
In summary, there is conflicting cross-sectional evidence
regarding the existence of a relationship between IR and
endothelial function in humans, but interventions that
modulate IR have been found to alter endothelial responses.
Ours is the first study to report such an effect of metformin.
Potential mechanisms for metformin’s beneficial effect.
The mechanism of this effect is uncertain. It is possible that
the reduction in IR directly accounts for the endothelial
effects, as we originally hypothesized. Given that our pa-
tients had only mild elevations in glucose levels, a secondary
effect due to reduction of endothelial cell glucose toxicity
seems unlikely. Coincident improvements in IR and other
aspects of vascular physiology are possible. In fact, met-
formin has recently been reported to have antioxidant effects
(34) in addition to the known favorable effects on circulating
lipids (10) and FFAs (35). However, no evidence links
alterations in these parameters with improvements in vas-
cular function separate from improvements in IR, and
therefore the hypothesis of the central role of IR remains
plausible. A direct metformin effect in vascular endothelial
cells is also possible, and supported by recent findings in
insulin-resistant rats (36). Also, in ex-vivo preparations of
vascular smooth muscle, a direct vasodilating action of
metformin has been reported, possibly due to altered cal-
cium handling (35,37,38).
Study limitations. We did not undertake any measure of
oxidative balance or oxidative stress, nor was LDL particle
size measured. These variables have significant impacts on
endothelial function and are potentially affected by met-
formin. Favorable changes could be contributing to the
observed improvement in endothelial function but were not
measured. This needs to be addressed in future studies.
Conclusions. In our group of patients with type 2 DM and
IR but without other metabolic abnormalities, we found
that treatment with metformin resulted in improved IR and
improved endothelial function. The principal dependence of
endothelium-dependent vasodilation on the degree of IR
following therapy argues in favor of a central role of IR in
vascular pathophysiology. This finding adds to our under-
standing of endothelial dysfunction in insulin-resistant
states, and also suggests a rational choice of antidiabetic
agent in patients with type 2 DM and vascular disease.
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